NICLOSAMIDE-LOADED LIPOSOMAL PLATFORMS AS BREAST ANTICANCER THERAPIES

Renata Faria Maia, PhD. student – Student, Biomedical Technology (BBT), University Medical Center Groningen (UMCG)/UG; Maria Lobita, PhD. student – Student, Biomedical Technology (BBT), University Medical Center Groningen (UMCG)/UG; Luigia Serpico, PhD. – Associated, Biomedical Technology (BBT), University Medical Center Groningen (UMCG)/UG; Mohammad-Ali Shahbazi, PhD. – Assistant Professor, Biomedical Technology (BBT), University Medical Center Groningen (UMCG)/UG; Hélder A. Santos, PhD. – Full Professor/PI, Biomedical Technology (BBT), University Medical Center Groningen (UMCG)/UG; Yareli Rojas Aguirre, PhD. – PI, Polymers, National Autonomous University of Mexico

Introduction:

Niclosamide is an FDA-approved anthelmintic drug in repositioning as anticancer agent [1] but its poor aqueous solubility limits its formulation development and clinical efficacy [2]. Liposomes are biocompatible vesicles that can overcome drug solubility limitations and optimize pharmacokinetic profiles [3]. Microfluidic technology enables the reproducible production of homogeneous nanosized liposomes, overcoming flaws of conventional methods [4]. Here, niclosamide-loaded liposomes (L-N) were fabricated by microfluidics as a step toward a liposomal platform for breast cancer therapy.